BWB Bluwater Bio

RNS Number:1472N
Bluewater Bio International
01 February 2008


1 February 2008


                          Bluewater Bio International
                         ("Bluewater" or "the Company")
                                        
                              Holdings in Company


The Company was notified today that following the disposal of its entire
shareholding in the Company, Corvus Capital Inc ("Corvus") no longer retains an
interest in the Company.

These shares, in addition to certain other shareholdings that have been disposed
of at the same time, are being  acquired by institutional shareholders. The
Company is pleased to announce that one of the acquirers is Lehman  Brothers,
who supported the Company in the fundraising that took place at the time of the
Company's admission to AIM in  December 2007, and who has, as a result,
increased its shareholding to 13,500,000 ordinary shares of 0.5p each, 
representing 6.3 per cent. of the issued share capital of the Company.

The shareholding acquired from Corvus will be the subject of an Orderly Market
Agreement, whereby dealings in such  shares requires the prior consent of the
Company's Nominated Adviser and Broker during the period up to December 2009.




Enquiries:

Daniel Ishag, CEO
Bluewater Bio International
Tel: +44(0)20 7751 4401

James Harris/Angela Peace
Strand Partners Limited
Tel: +44(0)20 7409 3494

Fiona Mulcahy/Sarah Gestetner
Citigate Dewe Rogerson
Tel: +44 207 282 2807



Notes for Editors:

Bluewater Bio International designs and markets an advanced biological solution
to the treatment of wastewater, called HYBACS. This system deploys a different
biological approach to any internationally established wastewater treatment
process. Through its design and operation, HYBACS biologically selects a
particular group of bacteria, Bacillus, with unusual natural properties which if
correctly stimulated exhibit higher biological reaction rates than other known
naturally occurring bacteria.

The Directors believe that HYBACS will be proven to be commercially superior to
the majority of existing treatment processes worldwide, and is able to treat
efficiently a wide range of organic industrial wastewaters, including highly
concentrated livestock wastewater and the effluent from, among others,
breweries, food processors, textile manufacturers, hospitals, factories and
residential developments.

Key benefits of the HYBACS system include:

  * HYBACS produces high quality treated wastewater, treating the biological
    waste in municipal wastewater down to 10 mg/L BOD (Biological Oxygen
    Demand), and up to 99 per cent. treatment of the biological waste in
    concentrated wastewaters;

  * HYBACS requires between five and 15 per cent. less capital expenditure
    than most widely installed comparable technologies to achieve these
    performance qualities on a like-for-like basis;

  * HYBACS requires between 22 and 30 per cent. less ongoing operating
    expenditure based on an overall lower energy consumption requirement on a
    like-for-like basis;

  * HYBACS is highly suited to plant retrofitting which makes HYBACS more
    suitable for various types of plant upgrading as compared to many other
    advanced modern wastewater treatment processes;

  * In applications where odour levels emanating from the plant may be an
    issue, the HYBACS process removes offensive odour without the requirement
    for additional deodorisation facilities which involve additional capital and
    operating expenditures; and

  * HYBACS removes approximately twice the concentration of E. coli
    bacteria, compared to conventional technology which may result in moderately
    reduced operating expenditure at sites where disinfection of the effluent is
    required.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
HOLTBMFTMMTMBIP

Bluwater Bio (LSE:BWB)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Bluwater Bio (LSE:BWB)
Historical Stock Chart
Von Jun 2023 bis Jun 2024